Clinical data | |
---|---|
Trade names | Badyket, Ivor, Hibor, Zibor, others |
AHFS/ Drugs.com | International Drug Names |
Routes of administration | Subcutaneous injection (except for haemodialysis) |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 96% (estimated) |
Elimination half-life | 5–6 hours |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
Chemical and physical data | |
Molar mass | 3600 g/mol (average) |
(what is this?) (verify) |
Bemiparin (trade names Ivor and Zibor, among others) is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH). [1]
Bemiparin is used for the prevention of thromboembolism after surgery, and to prevent blood clotting in the extracorporeal circuit in haemodialysis. [2]
The medication is contraindicated in patients with a history of heparin-induced thrombocytopenia with or without disseminated intravascular coagulation; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or pancreas impairment; and acute or subacute bacterial endocarditis. [2]
No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, aspirin and other NSAIDs, antiplatelet drugs, and corticosteroids. [2]
Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 g/mol on average. [3] ( Enoxaparin has 4500 g/mol.) These heparins have lower anti- thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding. [4]